Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Y Yu

Showing results (61-70 of 234) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancerEvan Y Yu, Kevin F Kuo, Roman Gulati, et al.
European Urology Open Science|January 5, 2023
Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level AnalysisFady Ghali, Yibai Zhao, Devin Patel, et al.
European Urology|June 18, 2024
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD TrialRuben Raychaudhuri, Makayla DeJong, Matthew Rettig, et al.
JAMA Oncology|June 4, 2021
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNAMichael T Schweizer, Smruthy Sivakumar, Hanna Tukachinsky, et al.
European Urology Focus|December 7, 2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 MutationsHeather H Cheng, Sam Callis, Evan Y Yu, et al.
Clinical Nuclear Medicine|February 3, 2011
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapyEvan Y Yu, Mark Muzi, Joy A Hackenbracht, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Complexities of Next-Generation Sequencing in Solid Tumors: Case StudiesAlexandra O Sokolova, Brian H Shirts, Eric Q Konnick, et al.
The Prostate|December 20, 2016
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate CancerAjjai Alva, Luke Nordquist, Stephanie Daignault, et al.
The Prostate|June 22, 2016
A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic CounselingHeather H Cheng, Nola Klemfuss, Bruce Montgomery, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
Pageof 24

Showing results (61-70 of 234) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancerEvan Y Yu, Kevin F Kuo, Roman Gulati, et al.
European Urology Open Science|January 5, 2023
Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level AnalysisFady Ghali, Yibai Zhao, Devin Patel, et al.
European Urology|June 18, 2024
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD TrialRuben Raychaudhuri, Makayla DeJong, Matthew Rettig, et al.
JAMA Oncology|June 4, 2021
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNAMichael T Schweizer, Smruthy Sivakumar, Hanna Tukachinsky, et al.
European Urology Focus|December 7, 2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 MutationsHeather H Cheng, Sam Callis, Evan Y Yu, et al.
Clinical Nuclear Medicine|February 3, 2011
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapyEvan Y Yu, Mark Muzi, Joy A Hackenbracht, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Complexities of Next-Generation Sequencing in Solid Tumors: Case StudiesAlexandra O Sokolova, Brian H Shirts, Eric Q Konnick, et al.
The Prostate|December 20, 2016
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate CancerAjjai Alva, Luke Nordquist, Stephanie Daignault, et al.
The Prostate|June 22, 2016
A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic CounselingHeather H Cheng, Nola Klemfuss, Bruce Montgomery, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
Pageof 24